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Introduction {#sec1}
============

Malaria caused by the protozoan parasite *Plasmodium falciparum* (Pf) remains a major public health menace, especially in young children in sub-Saharan Africa ([@bib51]). When an individual is bitten by a *Plasmodium*-infected mosquito, the parasite first replicates in hepatocytes and then initiates ∼48-h cycles of red blood cell (RBC) infection. In these RBCs, the parasite develops inside a parasitophorous vacuole, progressing from a ring into a highly metabolically active trophozoite and then a multinucleated schizont that yields 8--24 merozoites generated through asexual replication. Upon egress from the lysed host RBC, these merozoites infect new RBCs, with parasites capable of infecting up to 10%--20% of RBCs in an immunologically naive host ([@bib39]).

Chemotherapy remains a major pillar in the fight against malaria, alongside vector control, diagnosis, and access to treatment. The former first-line antimalarials chloroquine and sulfadoxine-pyrimethamine mainly affect trophozoites by inhibiting the hemoglobin catabolism pathway that provides nutrients for the parasite and the folate biosynthesis pathway that delivers the building blocks for DNA synthesis, respectively ([@bib7]). KAI407, a phosphatidylinositol 4-kinase (PI4K) inhibitor, is one of the more recent candidate antimalarials that specifically inhibit schizont development ([@bib30]). These drugs mostly target trophozoites and schizonts, which sequester in the microvasculature ([@bib32]). Compounds targeting ring stages, which circulate throughout the blood stream, are desirable to prevent further vasculature blockage. Artemisinins were the first clinical antimalarials with ring-stage activity, and artemisinin-based combination therapies have proven effective in reducing malaria death and case load ([@bib51]). However, parasites resistant to artemisinins and their partner drugs have emerged and are now undermining malaria control ([@bib31], [@bib42]). The discovery of antimalarials that hit novel targets and are active against multiple asexual blood stages, including rings, is thus of paramount importance.

Thousands of antimalarials with submicromolar potency have been identified in high-throughput whole-cell screens ([@bib4], [@bib13], [@bib20], [@bib23], [@bib40], [@bib41], [@bib53]), but target identification forms a major bottleneck for their further development into leads with increased target binding, selectivity, and whole-cell activity ([@bib34]). Metabolomic analysis of biochemical pathways affected upon compound exposure recently identified the mode of action of various candidate antimalarials from the Medicines for Malaria Venture Malaria Box ([@bib3]), and is a valuable tool to interrogate new screening hits. Combining this approach with other phenotypic assays can help explore the activity profile and therapeutic potential of candidate antimalarials.

The Malaria Drug Accelerator (MalDA) consortium aims to identify new antimalarial leads through *in vitro* phenotypic screens and the identification of novel assayable targets ([@bib4], [@bib12]). Within this context, we developed an assay that compares the stage-specific susceptibility of Pf asexual blood stage parasites and combined this with metabolomic profiling.

Results {#sec2}
=======

We designed a medium-throughput *in vitro* assay to quantitatively assess the susceptibility of the distinct stages of Pf intra-erythrocytic development. Highly synchronized 3D7-A10 parasites (that have an accelerated 40-h asexual blood stage cycle) were exposed to a range of compound concentrations for 8 h during the early ring, late ring, early trophozoite, late trophozoite, and schizont stages ([Figure 1](#fig1){ref-type="fig"}A). Assays were performed in 96-well plates, with a maximum in-well DMSO concentration of 0.35%. Cultures were continued to allow parasites to further develop in the absence of compound, extending through to invasion of new RBCs and development until the trophozoite stage. The total assay duration was 60 h. Parasites were stained with SYBR green and Mitotracker Deep Red and quantified by flow cytometry. Half-maximal inhibitory concentrations (IC~50~) were derived by non-linear regression analyses of the dose-response data. The IC~50~ value based on these 8-h exposures at specific asexual blood stages is referred to as the IC~50~^8h^, while the IC~50~ calculated from the standard 72-h exposure assay is the IC~50~^72h^.Figure 1Experimental Design for Asexual Blood Stage Specificity Profiling of Antimalarials and Profiles of Reference Drugs(A) Synchronized parasites were exposed for 8 h at the stages indicated. Survival at 60 h post-invasion was assessed by flow cytometry.(B) Unique stage specificity profiles of chloroquine, dihydroartemisinin, and KAI407. Bar plots indicate the IC~50~^8h^ when parasites were exposed only during the early ring, late ring, early trophozoite, late trophozoite, or schizont stage, with error bars showing the standard error of the mean based on at least three independent repeats. KAI407, a PI4K inhibitor. All data are available in [Table S1](#mmc1){ref-type="supplementary-material"}.

Light microscopy confirmed that the different periods of exposure corresponded to the different developmental stages and showed that the 32- to 40-h time point spanned schizont development, parasite egress, and reinvasion ([Figure 1](#fig1){ref-type="fig"}A), indicating that all asexual blood stages were profiled. The assay was further validated by the stage-specific susceptibility profiles of dihydroartemisinin, chloroquine, and KAI407, which showed the expected peak activity on early rings, rings and trophozoites, and schizonts, respectively ([@bib7], [@bib56]) ([Figure 1](#fig1){ref-type="fig"}B). The 35-fold difference in IC~50~^8h^ between schizonts and late trophozoites for KAI407 ([Table S1](#mmc1){ref-type="supplementary-material"}) highlighted the tight synchronization of parasites that is crucial for this assay.

The asexual blood stage susceptibility profile was determined for a set of 36 compounds that included licensed drugs, candidate antimalarials, compounds with a known target, and various screening hits (profiles of compounds are shown in [Figures 2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, [4](#fig4){ref-type="fig"}, and [5](#fig5){ref-type="fig"}, simplified molecular input line entry system descriptions for compounds are listed in [Table S2](#mmc1){ref-type="supplementary-material"}, and structures of compounds are displayed in [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}). Hits were selected from screens previously performed by the MalDA consortium (see [Table S2](#mmc1){ref-type="supplementary-material"} references) and prioritized based on their potency, chemical diversity, and unknown mode of action. Licensed antimalarial drugs and additional previously published preclinical compounds were included to provide more insights into their mode of action or to serve as a reference.Figure 2Detailed Asexual Blood Stage Susceptibility Profiles for Antimalarials with Peak Activity on All Rings or All Rings and TrophozoitesData for chloroquine and dihydroartemisinin can be found in [Figure 1](#fig1){ref-type="fig"}. Bar graphs indicate mean IC~50~^8h^ values, whereas survival graphs show the most representative curves from independent repeats. Error bars indicate the standard error of the mean based on \>3 independent repeats. Data are summarized in [Table S1](#mmc1){ref-type="supplementary-material"}.Figure 3Detailed Asexual Blood Stage Susceptibility Profiles for Antimalarials with Peak Activity on All TrophozoitesBar graphs indicate mean IC~50~^8h^ values, whereas survival graphs show the most representative curves from independent repeats. Error bars indicate the standard error of the mean based on \>3 independent repeats. Data are summarized in [Table S1](#mmc1){ref-type="supplementary-material"}.Figure 4Detailed Asexual Blood Stage Susceptibility Profiles for Antimalarials with Peak Activity on Late Trophozoites, or on All Trophozoites and SchizontsData for DSM265 and atovaquone, both compounds with peak activity at the late trophozoite stage, can be found in [Figure 5](#fig5){ref-type="fig"}. Bar graphs indicate mean IC~50~^8h^ values, whereas survival graphs show the most representative curves from independent repeats. Error bars indicate the standard error of the mean based on \>3 independent repeats. Data are summarized in [Table S1](#mmc1){ref-type="supplementary-material"}.Figure 5Late Trophozoites Are the Most Susceptible Stage to DSM265 and Atovaquone that Inhibit Pyrimidine Biosynthesis and the Mitochondrial Electron Transport Chain, Respectively(A) Overview of the pyrimidine biosynthesis and the mitochondrial electron transport chain pathways. DSM265 inhibits DHODH, whereas atovaquone inhibits cytochrome bc1 ([@bib22]).(B) Stage specificity profiles for DSM265 and atovaquone. IC~50~^8h^ values for (B) are available in [Table S1](#mmc1){ref-type="supplementary-material"}.

First, compounds were classified based on their timing of peak activity, defined as the asexual blood stage at which the compounds showed the lowest IC~50~^8h^ values. This identified compounds with peak activity during (1) all rings and trophozoites, (2) all rings, (3) all trophozoites, (4) all trophozoites and schizonts, (5) late trophozoites, and (6) schizonts ([Figure 6](#fig6){ref-type="fig"}). When compounds were classified by their overall activity profile based on identifying the specific stages that showed IC~50~^8h^ values \<1 μM ([Figure S3](#mmc1){ref-type="supplementary-material"}; [Table S1](#mmc1){ref-type="supplementary-material"}), seven active classes were identified: compounds active on (1) all asexual blood stages, (2) all rings and trophozoites, (3) late rings and all trophozoites, (4) all trophozoites and schizonts, (5) late trophozoites and schizonts, (6) only late trophozoites, and (7) only schizonts. Fosmidomycin, a moderately potent inhibitor of Pf isoprenoid biosynthesis ([@bib25]), as well as the hit compounds MMV000787, MMV019017, MMV020746, MMV022478, and MMV665939, showed IC~50~^8h^ values \>1 μM at all tested stages and therefore did not match any of these groups ([Table S1](#mmc1){ref-type="supplementary-material"}).Figure 6Stage of Peak Activity for Clinical and Experimental AntimalarialsPeak activity illustrates the period when the parasite was most susceptible to the tested compounds. MMV020746 and MMV665939 were omitted as their IC~50~^8h^ values were \>10 μM. All data are available in [Table S1](#mmc1){ref-type="supplementary-material"} and [Figures 1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, [4](#fig4){ref-type="fig"}, and [5](#fig5){ref-type="fig"}. ATQ, atovaquone; CQ, chloroquine; DHA, dihydroartemisinin; FQ, ferroquine; LMF, lumefantrine; MB, methylene blue; MQ, mefloquine; NQ, naphthoquine; PPQ, piperaquine.

The clinical antimalarials dihydroartemisinin, chloroquine, piperaquine, and lumefantrine showed little variation in IC~50~^8h^ values throughout the ring and trophozoite stages, and were consequently classified in the group with peak activity at ring and trophozoite stages. Although chloroquine, piperaquine, and lumefantrine IC~50~^8h^ values were similar for ring and trophozoite stages, survival curves for early rings were less steep than those for late rings and trophozoites ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). DSM265 and atovaquone, which are inhibitors of pyrimidine synthesis and the mitochondrial electron transport chain, respectively ([Figure 5](#fig5){ref-type="fig"}A), showed peak activity specifically during late trophozoite stages ([Figures 5](#fig5){ref-type="fig"}B and [6](#fig6){ref-type="fig"}). These mitochondrial inhibitors also displayed a biphasic survival curve at the early trophozoite and schizont stages that was not observed at other stages ([Figure 5](#fig5){ref-type="fig"}B; [Table S1](#mmc1){ref-type="supplementary-material"}).

MMV000442, MMV006455, MMV007181, and MMV665971 showed incomplete killing at all asexual blood stages, with evidence of initial growth inhibition at lower concentrations followed by demonstrably better growth at higher concentrations in the early and late ring stages ([Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}). This incomplete killing was not observed in the 72-h exposure survival curves for these compounds ([Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}). Aqueous solubility experiments for MMV000442, MMV006455, and MMV007181 indicated a solubility \>100 μΜ ([Table S3](#mmc1){ref-type="supplementary-material"}), well above the highest concentration used in the stage specificity assay.

To further examine whether the compound stage specificity profiles that we identified correlated with their mode of action, we examined the metabolic profile of 33 compounds ([Figure 7](#fig7){ref-type="fig"}; [Table S4](#mmc2){ref-type="supplementary-material"}). These consisted of 27 newly assayed compounds, plus another 6 (chloroquine, DSM265, MMV000248, MMV006455, MMV019017, and KAE609) for which data were already available ([@bib3]). In these experiments, we exposed trophozoite-infected RBCs to 10 × IC~50~^72h^ concentrations and then subjected parasite extracts to mass spectrometry-based metabolomic profiling ([@bib3]).Figure 7Metabolic Profiling of Compounds Identified Cellular Processes Targeted by CompoundsCompounds were clustered based on hydrophilic metabolite response to all measured metabolites (all data available in [Table S4](#mmc2){ref-type="supplementary-material"}). Compounds are listed only if they showed a \>2-fold change (log~2~ \> 1) in metabolite levels compared with untreated controls in at least one of the treated samples. Compounds are color-coded based on peak activity as shown in [Figure 6](#fig6){ref-type="fig"}. Metabolite data for chloroquine, DSM265, MMV000248, MMV006455, MMV019017, and KAE609 were sourced from ([@bib3]). Data for all other 27 compounds were generated in this study. ATQ, atovaquone; Cmpd, compound; CQ, chloroquine; DHA, dihydroartemisinin; FQ, ferroquine; LMF, lumefantrine; MB, methylene blue; mETC, mitochondrial electron transport chain; MQ, mefloquine; NQ, naphthoquine; PPQ, piperaquine.

Across all 33 compounds, we obtained quantitative data for 195 metabolites that represent major metabolic pathways, including but not limited to pyrimidine and purine synthesis, hemoglobin catabolism, folate biosynthesis, central carbon metabolism, glycolysis, and redox metabolism ([Table S4](#mmc2){ref-type="supplementary-material"}). Based on these metabolic profiles, compounds were hierarchically clustered via Ward clustering based on Pearson correlation coefficients to identify related metabolic signatures ([Figure 7](#fig7){ref-type="fig"}).

Several established metabolic signatures were observed among the analyzed compounds. Mitochondrial electron transport chain disruption is linked to inhibition of dihydroorotate dehydrogenase (DHODH) and cytochrome *bc*~1~ (CytBC1), leading to increases in the pyrimidine precursors dihydroorotate and N-carbamoyl-L-aspartate ([@bib3]). This metabolic signature was observed for DSM265 and ATQ, which respectively inhibit DHODH and CytBC1, as well as MMV000787, MMV021735, and MMV030666, for which the mode of action was previously unknown ([Figure 7](#fig7){ref-type="fig"}; [Table S4](#mmc2){ref-type="supplementary-material"}).

We performed resistance selections with MMV021735, MMV030666, and MMV000787 to compare their propensity for resistance with that of DSM265 and atovaquone, which have a relatively low minimum inoculum for resistance of 2 × 10^6^ and 2 × 10^7^parasites, respectively, when using 3 × IC~50~^72h^ drug concentrations ([@bib38]). Selections involving continuous exposure of 1 × 10^9^ Dd2-B2 parasites to a 3.5 × IC~50~^72h^ concentration of MMV000787, or intermittent drug pulsing in which parasites were exposed for several days at a time to 6 × IC~50~^72h^ concentrations of MMV000787 for 5 months, did not result in MMV000787-resistant parasites. For MMV021735, exposing 5 × 10^8^ 3D7-A10 parasites to 3 × IC~50~^72h^ concentrations in triplicate failed to yield resistant parasites. Exposing 5 × 10^8^ 3D7-A10 or Dd2-B2 parasites to 3 × IC~50~^72h^ concentrations of MMV030666 also failed to yield resistance. A ramping selection with 3D7-A10 parasites starting at 1 × IC~50~^72h^ and gradually increasing to 1.8 × IC~50~^72h^ over the course of 3 months also did not produce resistance. These data indicate that MMV000787, MMV21735, and MMV030666 have minimum inocula of resistance well above 5 × 10^8^ parasites.

Peptide decreases commonly linked with inhibition of hemoglobin endocytosis and/or catabolism within the digestive vacuole were also observed across multiple antimalarial compounds ([Figure 7](#fig7){ref-type="fig"}; [Table S4](#mmc2){ref-type="supplementary-material"}). This metabolic signature of decreased peptide levels (HVDD, PVNF, PEEK, PEE, DLS, SDL, SID, DLH, LD, PE, PD, SD, VD, and EV) was particularly pronounced for the compounds MMV022478, MMV019555, MMV667491, MMV030666, MMV000248, MMV006455, MMV007181, MMV020746, MMV000442, GNF-Pf-5660, KAE609, and MMV019017. Of these, MMV006455, MMV019017, and KAE609 also possessed increased levels of the deoxyribonucleotides dAMP and dTMP and decreased levels of cAMP. KAE609, and MMV019017 also showed decreased nucleoside di- and tri-phosphate levels (GDP, UDP, GTP, dATP, dGTP/ATP, and dUTP), which have previously been identified as a signature of inhibiting the Na^+^/H^+^-dependent ATPase PfATP4 ([@bib3]). The hemozoin inhibitor chloroquine did not show the expected strong hemoglobin catabolism signature, but instead showed a more modest decrease in peptide levels and clustered with the PfATP4-inhibitor KAE609.

Interestingly, the metabolic profile for MMV030666 indicated perturbation of both the mitochondrial electron transport chain and hemoglobin catabolism. MMV022224 induced increased levels of peptides, a profile that has not been observed before. Because of the peculiar profiles of these compounds, they were selected for an additional study in which synchronized parasites were exposed to 3× the IC~50~^8h^ of the most sensitive life stage at 8-h intervals, similar to the stage specificity assay, and cell morphology was assessed by microscopy at the end of each interval ([Figure S4](#mmc1){ref-type="supplementary-material"}). This showed MMV030666-exposed parasites to be most susceptible during the late trophozoite stage, as demonstrated by their bloated digestive vacuoles. This phenotype is characteristic of hemoglobin catabolism perturbation ([@bib43]), and is consistent with the metabolomics data. MMV022224-exposed parasites proved to be affected mostly during early and late trophozoite stages, without displaying swollen vacuoles. The health of ring-stage parasites, which showed similar IC~50~^8h^ values as trophozoites for MMV022224, was harder to microscopically evaluate due to their smaller size.

Mefloquine, naphthoquine, piperaquine, methylene blue, MMV675939, dihydroartemisinin, WLL-vs, MMV668311, ferroquine, and MMV085071 did not induce major changes within the set of metabolites detected in our study and, therefore, clustered in the low fold change group ([Figure 7](#fig7){ref-type="fig"}; [Table S4](#mmc2){ref-type="supplementary-material"}).

Discussion {#sec3}
==========

Herein we report the results of Pf asexual blood stage susceptibility assays that compared the susceptibility of early rings, late rings, early trophozoites, late trophozoites, and schizonts, for a set of 36 clinical and experimental antimalarials. These studies, which exposed each tightly synchronized stage for 8 h and assessed overall parasite growth at the same 60-h time point ([Figure 1](#fig1){ref-type="fig"}A), extend earlier experimental designs that assessed activity on a subset of stages or did not include wash-offs to restrict exposure to each stage ([@bib16], [@bib52]). Because compounds are washed out after each exposure moment and parasites are allowed to continue to grow in absence of compound until the end of the assay, the stage specificity assay quantifies the cytotoxic (killing) effect of compounds. The IC~50~^8h^ values are therefore in essence stage-specific half maximal lethal doses ([@bib35]). This contrasts with the IC~50~^72h^ values that are determined in assays that expose parasites continuously to compounds and measure the cytostatic (growth inhibitory) effect of compounds. Our results were combined with metabolomic profiling of the cellular pathway perturbations caused by these compounds, as an exploratory approach to identify common or unique profiles among the tested antimalarials. Classification of compounds according to the timing of their peak activity revealed a remarkable variety of profiles among both clinical and experimental compounds ([Figure 6](#fig6){ref-type="fig"}). As examples, the inhibitors DSM265 and atovaquone (which target DHODH and CytBC1, respectively) showed activity against late trophozoites only, and the PI4K inhibitor KAI407 showed activity against only schizonts, in good agreement with earlier studies ([@bib30], [@bib36], [@bib38]) ([Figures 1](#fig1){ref-type="fig"} and [5](#fig5){ref-type="fig"}; [Table S1](#mmc1){ref-type="supplementary-material"}).

Compounds with different chemical scaffolds that are known to target the same or related pathways showed similar stage specificity and metabolic profiles. This was especially apparent for atovaquone and DSM265 that act on related mitochondrial processes ([Figure 5](#fig5){ref-type="fig"}A). These agents also shared similar killing dynamics, with a monophasic survival curve for the highly sensitive late trophozoites and biphasic curves for early trophozoites and schizonts ([Figure 5](#fig5){ref-type="fig"}B). Of note, when parasite survival was assessed using only the SYBR green signal, and not the Mitotracker signal, we observed the same killing dynamics for atovaquone and DSM265. This likely reflects a dual purpose of the mitochondria of maintaining their membrane potential through the mitochondrial electron transport chain, required for the production of ATP, and enabling pyrimidine biosynthesis through DHODH ([Figure 5](#fig5){ref-type="fig"}A). Inhibition of DHODH by DSM265 will not only affect pyrimidine biosynthesis but also the recycling of ubiquinone, which is crucial for the parasite to maintain its mitochondrial membrane potential. Likewise, inhibition of CytB by atovaquone will not only directly affect the mitochondrial membrane potential, but also the recycling of ubiquinone and therefore the function of DHODH. DHODH and CytB are thus two distinct drug targets that are functionally linked. In accordance, DSM265 and atovaquone show the same stage specificity profile. Pyrimidines are most needed in late trophozoites when DNA synthesis peaks, allowing the production of daughter merozoites during schizogony ([@bib8]). Without pyrimidines, late trophozoites would not be able to develop into functional schizonts, resulting in a low IC~50~^8h^ and a smooth monophasic killing curve in late trophozoites ([Figure 5](#fig5){ref-type="fig"}B). In early trophozoites and schizonts, the dependency on pyrimidines is lower but a functional mitochondrial membrane potential would still appear to be vital for the many ongoing biological processes, leading to a biphasic response in which the first shift relates to pyrimidine biosynthesis and a second shift relates to the mitochondrial membrane potential. Early and late rings showed a monophasic response with high IC~50~^8h^ values, reflecting a parasite growth phase when pyrimidine biosynthesis and mitochondrial activity appear to be minimal. Atovaquone inhibition through membrane potential disruption was relatively ineffective in our 8-h exposure model, illustrating the need for longer compound exposure for mitochondrial electron transport chain inhibitors ([@bib21], [@bib36]). Importantly, incomplete killing by atovaquone and DSM265 was observed in all stages, matching previous data from recrudescence-based assays that showed atovaquone to be a slow and incomplete killer ([@bib28], [@bib44]).

Of note, the late trophozoite stage specificity profiles for ATQ and DSM265 are consistent with the timing of expression of their targets: *cytb* expression peaks during the late trophozoite stage, whereas maximal expression of *dhodh* spans early to late trophozoite stages ([@bib37]). The same holds true for KAE609, which targets PfATP4: transcription of *pfatp4* peaks at the early trophozoite stage ([@bib37]), consistent with KAE609 being inactive against rings yet active against early trophozoites and later stages. Interestingly, *pi4k*, which encodes the target of KAI407, is transcribed at fairly stable levels without showing a clear peak at any stage ([@bib37]). The schizont-specific activity profile of KAI407 may be determined by the availability of substrates that interact at this stage with PI4K.

These assays also differentiated the mode of action of chloroquine, piperaquine, and mefloquine, which share a core 4-aminoquinoline ring structure. Piperaquine essentially consists of two molecules of chloroquine connected by a central linker. Chloroquine and piperaquine are generally thought to act at the highly metabolically active trophozoite stage by inhibiting the biomineralization of free heme, released during hemoglobin digestion, into hemozoin, thereby causing a buildup of toxic free heme or heme-drug adducts ([@bib7]). Both chloroquine and piperaquine showed a similar stage specificity profile when the error margin is taken into account, and exerted potent growth inhibition in early ring stages. This would suggest that hemoglobin catabolism begins even in early rings, before the formation of the digestive vacuole inside which the bulk of hemozoin is generated. This inference is supported by a previous report ([@bib56]) and studies that detected hemoglobin uptake ([@bib19]) and activity of falcipains (required for hemoglobin digestion \[[@bib54]\]) in very early rings. Notably, early rings showed a flatter slope of the dose-dependent curve than late rings and trophozoites, indicating different growth inhibitory dynamics ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). Metabolic perturbation profiles, nonetheless, revealed a strikingly different profile for chloroquine and piperaquine ([Figure 7](#fig7){ref-type="fig"}; [Table S4](#mmc2){ref-type="supplementary-material"}). Chloroquine induced various perturbations that were not observed under piperaquine pressure, such as \>2-fold increased levels of dAMP, dUTP, cytidine, xanthosine, and N-acetyl-lysine, decreased *p*-hydroxybenzoate levels, and decreased peptide levels that are characteristic for hemoglobin catabolism inhibition. Some of these metabolic changes in chloroquine-exposed parasites, such as the increased dAMP levels, caused chloroquine to metabolically cluster with the PfATP4 inhibitor KAE609 and other compounds that cause an overall disturbance in cellular homeostasis. This clustering, however, is based on rather modest changes and should be interpreted with caution. Piperaquine metabolically clustered with other compounds that induced an overall low differential fold change ([Figure 7](#fig7){ref-type="fig"}; [Table S4](#mmc2){ref-type="supplementary-material"}). The only notable changes were ≥2-fold decreased levels of dCDP, dTMP, guanosine, and guanine. This suggests that piperaquine might have an additional mode of action beyond inhibition of hemozoin formation that perturbs purine and pyrimidine metabolism.

Mefloquine, an arylamino alcohol that also shares a quinoline ring, was earlier reported to inhibit hemozoin formation in parasites at a lower level than chloroquine ([@bib11]), possibly because of reduced mefloquine accumulation in the digestive vacuole. Earlier studies examining mefloquine and its relationship to the primary resistance determinant PfMDR1 (located on the membrane of the digestive vacuole) suggested that mefloquine acts primarily outside the digestive vacuole ([@bib50]). The difference in mode of action between mefloquine and chloroquine is also reflected in their stage specificity and metabolomics profiles, with mefloquine showing peak activity only in trophozoites and clustering separately from other compounds affecting hemoglobin catabolism ([Figure 7](#fig7){ref-type="fig"}). These data further support the notion that the target of mefloquine is presumably located outside of the digestive vacuole, affecting the parasite in ways that could not be detected by our metabolomics study.

The clinical antimalarial lumefantrine displayed peak activity during both rings and trophozoites, similar to chloroquine and piperaquine but different from the trophozoite-only peak activity of mefloquine. Metabolically, lumefantrine induced minor peptide increases and clustered with GNF-Pf-5660, which is known to affect hemoglobin uptake without directly targeting hemozoin formation ([@bib49]). The different stage specificity and metabolic profiles between lumefantrine and mefloquine suggest distinct mode of actions, despite PfMDR1 being a determinant of low-level resistance to both ([@bib17]).

Methylene blue is known to act as a redox cycler and is used clinically to treat methemoglobinemia via its reduction of Fe^3+^ to Fe^2+^ ([@bib6]). Methylene blue also binds hematin (a precursor of hemozoin crystals) at low micromolar concentrations *in vitro* ([@bib6]). Our finding of similar stage specificity and metabolomic profiles between methylene blue and piperaquine suggest that both could affect heme detoxification and hemozoin formation, albeit via different mechanisms. Methylene blue potentially causes a reduction of Fe^3+^, whereas piperaquine is presumed to bind Fe^3+^-heme and prevent its incorporation into chemically inert hemozoin ([@bib14]). Methylene blue, in contrast to piperaquine, is also potent against mature gametocytes that are not thought to degrade hemoglobin ([@bib1]), implying an additional mode of action for methylene blue that might affect additional redox cycling agents such as NADPH levels ([@bib46]).

Interestingly, ferroquine and naphthoquine, which are both chloroquine derivatives that are currently part of artemisinin-based combination therapies under clinical trials ([@bib24], [@bib48]), shared a unique stage specificity profile showing peak activity during early rings and a gradual increase of IC~50~^8h^ values through to schizonts ([Figure 2](#fig2){ref-type="fig"}). Ferroquine has hemozoin inhibitory activity similar to chloroquine and has been shown to induce the formation of hydroxyl radicals via the Fenton reaction, leading to lipid peroxidation and exacerbating oxidative stress in the parasite ([@bib5], [@bib9], [@bib15]). This additional mode of action might contribute to the unique stage-specific profile of ferroquine action. The mode of action of naphthoquine is less understood. Even though parasites exposed to naphthoquine and ferroquine did not reveal major changes in the levels of detected metabolites thus causing them to cluster in the low fold change metabolic group ([Figure 7](#fig7){ref-type="fig"}), their shared and distinctive stage specificity profiles suggest a common target or pathway.

Compounds with peak activity during ring stages are highly desired. In our assays, naphthoquine, ferroquine, and WLL-vs showed peak activity specifically during ring stages, whereas chloroquine, piperaquine, methylene blue, dihydroartemisinin, lumefantrine, GNF-Pf-5660, MMV022224, and MMV668311 showed peak activity in rings and trophozoites. This diversity among ring-active compounds suggests the presence of multiple druggable processes in rings, despite this stage being considered less metabolically active ([@bib3]) than trophozoites. One such process involves the proteasome, since the ring-active compound WLL-vs specifically binds to and inhibits the β2 and β5 subunits of the Pf 26S proteasome ([@bib27], [@bib47]). Other processes that appear to begin early in rings include hemoglobin endocytosis and catabolism ([@bib19], [@bib49], [@bib54]).

We note that WLL-vs, included in our study, is a covalent binder of the Pf 26S proteasome inhibitor, meaning that wash-out protocols would have little effect on its irreversible mode of action. Previous studies on *Plasmodium* have shown that mRNA transcripts are produced in a "just-in-time" fashion, i.e., when they are needed for the parasite\'s development ([@bib37]). This would suggest that the chances of falsely detecting early stage activity are minimal. However, a lingering effect after drug wash-out could theoretically result in overestimating compound activity during later stages. For this reason, we have included five different time points at which compound exposure was started, followed by drug wash-outs, to minimize compound carry over. This approach was validated with our WLL-vs data, which showed lower IC~50~^8h^ values in rings compared with trophozoites and schizonts ([Figure 2](#fig2){ref-type="fig"}).

An established high-priority mode of action is inhibition of mitochondrial functions, targeting either DHODH (DSM265) or CytBC1 (atovaquone) ([@bib22]) ([Figure 5](#fig5){ref-type="fig"}A). Both, however, yield resistance at low inocula, which in patients translates into an increased risk of treatment failure using these classes of inhibitors ([@bib29], [@bib33]). The experimental compounds MMV000787, MMV021735, and MMV030666 showed peak activity in late trophozoites, albeit with incomplete killing, and shared the same distinct metabolic profile of increased dihydroorotate and N-carbamoyl-L-aspartate levels and decreased orotidine 5-P levels ([Figure 7](#fig7){ref-type="fig"}; [Table S4](#mmc2){ref-type="supplementary-material"}) that is characteristic for DHODH and CytBC1 inhibition ([@bib3]). Interestingly, selections with these former compounds failed to yield resistant parasites, even at high inocula of 5 × 10^8^ parasites. They also did not show the biphasic curves observed for atovaquone and DSM265. These data raise the possibility that inhibition of mitochondrial pathways might be achievable through mode of actions that are distinct from DHODH and CytBC1 and that are less prone to acquisition of resistance. In addition to the metabolic signature of mitochondrial inhibition, MMV030666 also induced decreased peptide levels ([Table S4](#mmc2){ref-type="supplementary-material"}), causing it to metabolically cluster with compounds inhibiting hemoglobin catabolism ([Figure 7](#fig7){ref-type="fig"}). However, MMV030666 still maintained a late trophozoite stage-specific activity profile similar to that of DSM265 and atovaquone but distinct from the overall trophozoite or ring plus trophozoite peak activity profiles usually observed for the majority of compounds with a hemoglobin catabolism metabolic signature ([Figures 4](#fig4){ref-type="fig"}, [5](#fig5){ref-type="fig"}, and [7](#fig7){ref-type="fig"}; [Table S4](#mmc2){ref-type="supplementary-material"}). Cell morphological analysis of MMV030666-exposed parasites ([Figure S4](#mmc1){ref-type="supplementary-material"}) identified late trophozoites as the most sensitive intra-erythrocytic stage, consistent with mitochondrial inhibition, but also showed a bloated digestive vacuole that is characteristic for inhibitors of hemoglobin catabolism ([@bib43]).

Most hits that clustered within the hemoglobin catabolism group, characterized by decreased peptide levels ([@bib3]), showed peak activity in trophozoites (MMV027496, MMV019555, MMV000248, MMV006455, MMV007181, and MMV000442). The exceptions were GNF-Pf-5660 ([@bib49]), lumefantrine, and MMV665794, which showed peak activity against rings and trophozoites. This observation, plus additional metabolic changes induced by MMV019555, highlights the potential diversity in mode of actions among compounds showing hemoglobin catabolism perturbation.

Among all compounds tested, MMV022224 was unique both in its metabolomic fingerprint and its stage specificity. Exposure to MMV022224 caused increased peptide levels and only this compound showed activity exclusively in rings and trophozoites but not in schizonts. Peptide accumulation may suggest a metabolic disruption further downstream in the hemoglobin catabolism pathway, possibly of an aminopeptidase or transporter. These unique profiles highlight MMV022224 as an attractive hit from a discovery and development perspective.

It is important to note that the metabolomics experiments in this study were exploratory in nature, involving one to two biological replicates to screen for known and novel candidate mode of actions within a large set of compounds. Once compounds are selected and prioritized for further discovery or development studies, these metabolomics data should be complemented with targeted in-depth follow-up studies to validate candidate targets and mode of actions as demonstrated recently for a new class of pantothenamides ([@bib45]).

The asexual blood stage susceptibility profiles of compounds may also help determine whether a protein is a target or solely a resistance mechanism. Resistance selections with MMV675939, MMV665939, and MMV020746 all identified SNPs or copy-number variations in the ABC transporter I family member 1, also known as ABCI3 (PF3D7_0319700) ([@bib12]). MMV675939 was most active on early and late trophozoites with IC~50~^8h^ values that were only 2-fold higher than the IC~50~^72h^ value, while MMV020746 and MMV665939 showed IC~50~^8h^ values that were \>28-fold higher than the IC~50~^72h^ ([Table S1](#mmc1){ref-type="supplementary-material"}). This contrast between the timing of peak activity for MMV675939 and the two other compounds suggests that they have different modes of actions and that ABCI3 is solely a resistance mediator and not the target.

Asexual blood stage susceptibility profiling may also help prioritize screening hits. Compounds with potent IC~50~^8h^ values across all stages are of particular interest for further development as such activity profiles might compensate for a faster clearance or other pharmacokinetic-related issues that reduce *in vivo* exposure time. Dihydroartemisinin and piperaquine, two first-line antimalarial drugs, showed activity on all stages with IC~50~^8h^ values at the most susceptible stages that were within 2-fold of their IC~50~^72h^ values ([Table S1](#mmc1){ref-type="supplementary-material"}). Chloroquine, mefloquine, and lumefantrine showed larger IC~50~^8h^ over IC~50~^72h^ ratios, but with IC~50~^8h^ values still \<300 nM ([Table S1](#mmc1){ref-type="supplementary-material"}). Based on these parameters, ferroquine, WLL-vs, and GNF-PF-5660 represent promising antimalarial scaffolds. WLL-vs is of particular interest given its selectivity for the parasite proteasome and the fact that resistance is rare and low-grade ([@bib27], [@bib47], [@bib55]). Ferroquine has shown promising efficacy in phase II trials ([@bib48]) and our assays indicated a unique ring-active profile that underscores its potential. With GNF-Pf-5660, chemical derivatization efforts are underway to improve its partial *in vivo* efficacy, established in rodent malaria models ([@bib49]).

Compounds that show IC~50~^8h^ values orders of magnitude larger than IC~50~^72h^ values are potentially of less interest as these may have multiple mode of actions throughout intra-erythrocytic development and/or require longer exposures to achieve full killing. In addition, such a profile indicates that the short exposures usually applied for metabolomics will likely yield a less informative response. None of the current clinical or advanced candidate antimalarials showed this profile, suggesting that this is indeed a good de-prioritization criterion for further development. Examples of experimental compounds with such an unfavorable profile in our dataset were MMV022478 and MMV019017 ([Figure 4](#fig4){ref-type="fig"}), and MMV665939 and MMV020746, which showed IC~50~^8h^ values \>10 μΜ at all stages (data not shown) ([Table S1](#mmc1){ref-type="supplementary-material"}).

MMV000442, MMV006455, MMV007181, and MMV665971 showed a peculiar profile in early and late ring stages, with initial growth inhibition at lower compound concentrations that reverses to less inhibition at higher concentrations ([Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}). Solubility assays with MMV0004442, MMV006455, and MMV665791 indicated that these compounds have an aqueous solubility \>100 μΜ, indicating that these survival curves are not due to solubility issues. This phenomenon has been observed in other chemical series and can at times be overcome through lead optimization ([@bib26]). Despite their undesirable dose-response curves, these compounds might therefore still prove valuable as starting points for drug discovery efforts.

The asexual blood stage specificity profiles can also inform the selection of partner drugs for combination therapies. Ideally, combinations would target all different asexual blood stages. As an example, schizont-specific compounds could be partnered with compounds that target rings and trophozoites. These profiles can also be used to devise strategies to delay the emergence of resistance. For example, the late trophozoite-active compound DSM265 could be combined with another compound with a broader activity profile including late trophozoite to delay the emergence of DSM265 resistance ([@bib29]).

In summary, integrating investigations into antimalarial stage-specific mode of actions including metabolic perturbations into drug discovery and development programs should benefit ongoing efforts to develop new medicines to counter the spread of antimalarial multidrug resistance, as part of the mission to eliminate this disease.

Significance {#sec4}
============

**With the increasing spread of *Plasmodium falciparum* resistance to artemisinins and their partner drugs, the development of antimalarials with new modes of actions is more critical than ever. High-throughput screens are able to identify potent chemical scaffolds, but not knowing their target often hampers their further development. Malaria drug discovery pipelines would thus greatly benefit from new assays that interrogate the mode of action and activity profile of screening hits. We designed an approach that provides more resolution into the different modes of action of clinical and experimental antimalarials by identifying the specific moment of asexual blood stage development against which these compounds are most active and combining this with a metabolomics assessment of pathway perturbations. This identified several stage specificity profiles that correlated well with inhibition of particular metabolic pathways. Interestingly, we also identified compounds that act on similar pathways albeit through different targets. Aside from generating insights into the tested clinical antimalarials, this approach also offered a rationale for the prioritization of experimental compounds. Our study identified several hits from the Malaria box and the Malaria Drug Accelerator consortium that showed promising antimalarial profiles for further development, especially in the context of combination therapies. Importantly, this approach can also be adopted for other pathogens that undergo multiple differentiation steps within their host.**

STAR★Methods {#sec5}
============

Key Resources Table {#sec5.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Chemicals, Peptides, and Recombinant Proteins**All tested antimalarials and their structures are available in [Table S2](#mmc1){ref-type="supplementary-material"} and [Figure S2](#mmc1){ref-type="supplementary-material"}.**Experimental Models: Cell Lines**Parasite line 3D7-A10Goldberg lab at Washington State Univesity, St. Louis, USA3D7-A10Parasite line 3D7-MR4Malaria Research and Reference Reagent Resource CenterCat\#MRA-104Parasite line Dd2-B2Wellems Lab at NIAID, MD, USADd2-B2**Other**All tested antimalarials and their structures are available in [Table S2](#mmc1){ref-type="supplementary-material"} and [Figure S2](#mmc1){ref-type="supplementary-material"}.**Software and Algorithms**GraphPad Prism 8GraphPad Software, San Diego, CA, USA[www.graphpad.com](http://www.graphpad.com){#intref0010}El-MAVEN[@bib2]<https://elucidatainc.github.io/ElMaven/>RStudio[@bib58]<http://www.rstudio.com/>Metaboanalyst[@bib10]<https://www.metaboanalyst.ca/>Hyperspec[@bib57].<http://hyperspec.r-forge.r-project.org>Suprahex R[@bib59]<http://supfam.org/supraHex>

Lead Contact and Materials Availability {#sec5.2}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Manu Vanaerschot (<manu.vanaerschot@gmail.com>). Please note that availability of experimental compounds may be restricted and might require resynthesis. All chemical structures as well as SMILES for each compound are available in [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"} and [Table S2](#mmc1){ref-type="supplementary-material"}.

Experimental Model and Subject Details {#sec5.3}
--------------------------------------

The Pf parasites used in this study were cultured in human O^+^ blood (sex of donor unknown) at 3% hematocrit in RPMI-1640 media supplemented with 50 μM hypoxanthine, 2 g L^-1^ sodium bicarbonate, 2 mM L-glutamine, 25 mM HEPES, 0.5% AlbuMAXII (Invitrogen) and 10 μg mL^-1^ gentamycin in 5% O~2~, 5% CO~2~ and 90% N~2~ at 37°C. The 3D7-A10 Pf line is a clone of the 3D7 line received from the Goldberg lab at Washington State University in St. Louis. The 3D7-MR4 line was obtained from the Malaria Research and Reference Reagent Resource Center (MR4, Cat\#MRA-102). The Dd2-B2 Pf line is a clone obtained by limited dilution from the Dd2 line provided by Dr. Thomas Wellems (NIAID, NIH).

Method Details {#sec5.4}
--------------

### Stage Specificity Assay {#sec5.4.1}

Standard asexual blood stage susceptibility results were collected by exposing asynchronous 3D7-A10 parasite cultures to 10 different concentrations plus no-compound controls for 72 hr. To determine the specific asexual blood stage at which the compounds are active, schizonts were magnetically purified using MACS LD columns (Miltenyi Biotec) from cultures that had been repeatedly synchronized with 5% sorbitol. After a 3hr incubation at 2% hematocrit to allow re-invasion, cultures were again sorbitol-synchronized to obtain a pure ring-stage culture (time = 0 hr). These parasites were then plated in five 96-well plates and exposed to compounds (SMILES and origin listed in [Table S2](#mmc1){ref-type="supplementary-material"}, structures shown in [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}) as early rings (0-8 hr), late rings (8-16 hr), early trophozoites (16-24 hr), late trophozoites (24-32 hr) or schizonts (32-40 hr). Incubation times were adjusted to the 40 hr asexual blood stage cycle of the 3D7-A10 parasite line. Synchronicity of the cultures was confirmed by imaging on average 83 parasites per time point in control conditions. Compounds were removed through three rounds of washing including two plate changes in 37°C prewarmed culture media after each exposure. All pipetting steps to expose and wash parasites were performed using a Tecan Freedom Evo 100 for increased throughput and accuracy. Each group of plates per timepoint were placed in a separate humidified chamber to avoid any delay in growth rate due to temperature variations. For the stage specificity assay, growth inhibition was assessed at the 60 hr time point at which parasites had expanded, reinvaded new RBCs, and developed into the trophozoite stage that allows straight-forward quantification by flow cytometry. This is very similar to the standard 72 hr assay in which parasites are not synchronized, but also allowed to reinvade and develop further for another half life cycle. Parasite survival for both the 72 hr and stage-specific 8 hr exposures was assessed by SYBR Green and MitoTracker Deep Red FM staining (Life Technologies) and subsequent flow-cytometric analysis (Accuri C6, BD Biosciences) ([@bib18]). IC~50~ values were derived from growth inhibition data using nonlinear regression (Prism 7, GraphPad). All asexual blood stage assays were repeated on at least three independent occasions with two technical replicates.

### Culturing for Metabolomics {#sec5.4.2}

3D7-MR4 parasites were cultured at 50 ml volumes and 2% hematocrit as described elsewhere ([@bib3]). Cultures were kept at the appropriate temperature and gas mixture in incubators between media exchange, culture division, and synchronization. Synchronization was achieved via 5% sorbitol. All reagents and experimental spaces were mycoplasma-free, and reagents passed through 0.2 μm liquid filters when possible prior to use.

### Metabolomics {#sec5.4.3}

Hydrophilic metabolite changes in response to compound exposure were profiled as previously described ([@bib3]). Treatments were performed on 1 × 10^8^ MACS-purified, synchronized trophozoite parasite-infected RBCs (24-36 hr post invasion) in 5 mL RPMI. Compounds were added at a concentration of 10 × IC~50~^72hr^ and incubated for 2.5 hr. All treatment conditions were performed as technical triplicates and included an untreated control. Subsequently, PBS washes were performed, and infected RBCs were extracted with 90% methanol containing 0.5 μM ^13^C^15^N-labelled aspartate as an internal standard, then dried under nitrogen and stored at -80°C. Process blanks were generated at the time of extraction in technical triplicates. Samples were then resuspended in high-performance liquid chromatography (HPLC) grade water containing 1 μM chlorpropamide as an additional internal standard and analyzed by ultra-high-performance liquid chromatography mass spectrometry UHPLC-MS as described ([@bib3]).

### Targeted Analysis {#sec5.4.4}

Following negative ionization analysis of hydrophilic extracts on a Thermo Exactive Plus Orbitrap, sample data were converted and transferred for analysis. Targeted peak picking from a curated list of 298 metabolites was achieved using el-MAVEN software (<https://elucidatainc.github.io/ElMaven/> ([@bib2])), followed by normalization and analysis via RStudio (<http://www.rstudio.com/>) and Metaboanalyst (<https://www.metaboanalyst.ca/> ([@bib10])). Data were visualized using the Hyperspec (<http://hyperspec.r-forge.r-project.org>) and Suprahex R ([@bib59]) scripting packages in RStudio. Hierarchical clustering of the metabolic profiles to identify related metabolic signatures was performed using the Ward method, based on the Pearson correlation coefficients, by the Hyperspec R integrated heatmap function.

### Resistance Selections {#sec5.4.5}

Attempts to obtain parasites resistant to MMV030666, MMV000787 and MMV021735 were performed using either single step (continuous) or ramping selection protocols as described elsewhere ([@bib12]). For single step selections, parasites are continuously exposed to relatively high concentrations of the compound of interest (usually 3 × IC~50~) with culture media and RBCs being regularly refreshed until actively growing parasites are again observed. Cultures were monitored for minimum 70 days after start of exposure. For ramping selections, parasites are exposed at low compound concentrations (usually 1 × IC~50~ or lower) and parasite growth is continuously monitored. When parasites seem to have adapted to the pressure, compound concentrations are gradually increased to adapt parasites to even higher levels of compound. Standard IC~50~^72hr^ assays were performed on recrudesced parasites from single step selections, if any, and on parasites resulting from ramping selections.

### Solubility Assay {#sec5.4.6}

The aqueous solubility of MMV007181, MMV000442 and MMV006455 was determined at a single concentration of 500 μM because of compound scarcity. The protocol used was adapted from Millipore Corporation's "MultiScreen® Solubility Filter Plate" application note. Dihydroartemisinin, chloroquine and piperaquine were used as controls. Briefly, compounds were first dissolved in DMSO at 10 mM. They were then added to 1 × PBS (pH 7.4) at a 1:20 ratio in 1.5 ml tubes and mixed on a shaker (100 rpm) at room temperature for 1.5 hr. They were then filtered using Target2 regenerated cellulose 0.2 μM filters (Thermal Scientific, part number F2500-8) to remove any precipitate. 160 μl of the filtrate was dispensed into flat-bottomed 96-well culture plates and diluted with 40 μl/well acetonitrile. The plate was then placed on a shaker (100 rpm) at room temperature for 10 min. After mixing, the filtrate was analyzed using a Spectramax 340PC (Molecular Devices) at 280, 300, 320, 340, 360 and 800 nm. Standards were made by adding compounds into standards buffer (80:20 1 × PBS: acetonitrile, pH 7.4) at a 1:25 ratio. The mixtures were allowed to mix on a shaker (100 rpm) for 10 min at room temperature and analyzed at the same six wavelengths as mentioned above. The aqueous solubility of compounds was then determined by calculating the ratio of absorbances between the filtrate and the standard using the formula below:$$\frac{\left( {\sum{\text{AU}\ \text{at}\ 280,\ 300,\ 320,\ 340,\ 360\ \text{nm}}} \right) - \left( {\text{AU}\ \text{at}\ 800\ \text{nm}} \right)\ \text{Filtrate}}{\left( {\sum{\text{AU}\ \text{at}\ 280,\ 300,\ 320,\ 340,\ 360\ \text{nm}}} \right) - \left( {\text{AU}\ \text{at}\ 800\ \text{nm}} \right)\ \text{Standard}}$$

If the ratio is ≈ 1, a compound's aqueous solubility is ≥ 500 μM. Ratios \< 1.0 and \> 0.5 indicate a solubility between 100 μM and 500 μM, while ratios ≤ 0.5 indicate a solubility ≤ 100 μM.

Quantification and Statistical Analysis {#sec5.5}
---------------------------------------

All details of the stage specificity experiments, including the number of biological (n), can be found in [Table S1](#mmc1){ref-type="supplementary-material"}. The standard error of the mean (SEM) was used to report error values for means based on multiple independent repeats. Details on the number of repeats of the metabolomics study can be found in the legend of [Table S4](#mmc2){ref-type="supplementary-material"}. This study did not perform any other statistical methods on the data.

Data and Code Availability {#sec5.6}
--------------------------

The published article includes all datasets generated in this study. The IC~50~ data and survival curves are available in [Table S1](#mmc1){ref-type="supplementary-material"} and [Figures 1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, [4](#fig4){ref-type="fig"}, and [5](#fig5){ref-type="fig"}. Metabolomics data is available in [Table S4](#mmc2){ref-type="supplementary-material"}.

Supplemental Information {#appsec2}
========================

Document S1. Figures S1--S4 and Tables S1--S3Table S4. Metabolomics Dataset, Related to Figure 7Data shown are the log~2~ changes in metabolites levels under compound pressure compared with untreated controls. Metabolomics data were generated specifically for this study, except for CQ, DSM265, MMV000248, MMV006455, MMV019017, and KAE609, which were sourced from ([@bib3]). Data for ATQ is based on \>10 independent repeats. Data for CQ, DSM265, MMV000787, MMV007181, MMV019555, MMV020746, MMV665939, MMV675939, and KAE609 are based on two independent repeats. Data for other compounds are based on one biological repeat. ATQ, atovaquone; CQ, chloroquine; DHA, dihydroartemisinin; FQ, ferroquine; LMF, lumefantrine; MB, methylene blue; NQ, naphthoquine; MFQ, mefloquine; PPQ, piperaquine.Document S2. Article plus Supplemental Information
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